{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:43:11Z","timestamp":1766983391134,"version":"3.41.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11359-7","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:01:18Z","timestamp":1753948878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of tenofovir on clinical outcomes of COVID-19 patients: a systematic review"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-3850","authenticated-orcid":false,"given":"Tha\u00eds Lorenna Souza","family":"Sales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3124-9322","authenticated-orcid":false,"given":"Daniella Nunes","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-5604","authenticated-orcid":false,"given":"Virginia Mara Reis","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6638-7979","authenticated-orcid":false,"given":"Gabriel Gouveia","family":"de Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4278-3771","authenticated-orcid":false,"given":"Milena Soriano","family":"Marcolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"11359_CR1","unstructured":"Datadot [Internet]. [cited 2024 Aug 14]. COVID-19 cases. Available from: http:\/\/data.who.int\/dashboards\/covid19\/cases"},{"key":"11359_CR2","doi-asserted-by":"publisher","unstructured":"Haileamlak A. The impact of COVID-19 on health and health systems. Ethiop J Health Sci [Internet]. 2021;31(6):1073\u20134. Available from: https:\/\/doi.org\/10.4314\/ejhs.v31i6.1","DOI":"10.4314\/ejhs.v31i6.1"},{"key":"11359_CR3","doi-asserted-by":"publisher","unstructured":"Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol [Internet]. 2020;30(3):313\u201324. Available from: https:\/\/doi.org\/10.4014\/jmb.2003.03011","DOI":"10.4014\/jmb.2003.03011"},{"key":"11359_CR4","doi-asserted-by":"publisher","unstructured":"M\u00f8lhave M, Agergaard J, Wejse C. Clinical Management of COVID-19 Patients - An Update. Semin Nucl Med [Internet]. 2022;52(1):4\u201310. Available from: https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.06.004","DOI":"10.1053\/j.semnuclmed.2021.06.004"},{"key":"11359_CR5","doi-asserted-by":"publisher","unstructured":"Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol [Internet]. 2023;14:1125246. Available from: https:\/\/doi.org\/10.3389\/fimmu.2023.1125246","DOI":"10.3389\/fimmu.2023.1125246"},{"key":"11359_CR6","unstructured":"Diseases C. Clinical management of COVID-19: Living guideline, 18 August 2023 [Internet]. World Health Organization; 2023 [cited 2024 Aug 14]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2023.2"},{"key":"11359_CR7","doi-asserted-by":"publisher","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov [Internet]. 2023;22(6):449\u201375. Available from: https:\/\/doi.org\/10.1038\/s41573-023-00672-y","DOI":"10.1038\/s41573-023-00672-y"},{"key":"11359_CR8","unstructured":"Website. [Internet]. Available from: https:\/\/wwww.uptodate.com\/contents\/covid"},{"key":"11359_CR9","unstructured":"COVID-19 Treatment Guidelines [Internet]. [cited 2024 Aug 14]. Information on COVID-19 Treatment, Prevention and Research. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"key":"11359_CR10","doi-asserted-by":"publisher","unstructured":"Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Therapeutics for COVID-19. Nat Microbiol [Internet]. 2023;8(5):771\u201386. Available from: https:\/\/doi.org\/10.1038\/s41564-023-01356-4","DOI":"10.1038\/s41564-023-01356-4"},{"key":"11359_CR11","doi-asserted-by":"publisher","unstructured":"Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents [Internet]. 2020;55(5):105955. Available from: https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105955","DOI":"10.1016\/j.ijantimicag.2020.105955"},{"key":"11359_CR12","doi-asserted-by":"publisher","unstructured":"Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol [Internet]. 2020;72(9):1145\u201351. Available from: https:\/\/doi.org\/10.1111\/jphp.13273","DOI":"10.1111\/jphp.13273"},{"key":"11359_CR13","doi-asserted-by":"publisher","unstructured":"Hua Y, Dai X, Xu Y, Xing G, Liu H, Lu T et al. Drug repositioning: Progress and challenges in drug discovery for various diseases. Eur J Med Chem [Internet]. 2022;234:114239. Available from: https:\/\/doi.org\/10.1016\/j.ejmech.2022.114239","DOI":"10.1016\/j.ejmech.2022.114239"},{"key":"11359_CR14","doi-asserted-by":"publisher","unstructured":"Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res [Internet]. 2022;22(1):970. Available from: https:\/\/doi.org\/10.1186\/s12913-022-08272-z","DOI":"10.1186\/s12913-022-08272-z"},{"key":"11359_CR15","doi-asserted-by":"publisher","unstructured":"Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med [Internet]. 2011 Apr-Jun;57(2):153\u201360. Available from: https:\/\/doi.org\/10.4103\/0022-3859.81870","DOI":"10.4103\/0022-3859.81870"},{"key":"11359_CR16","doi-asserted-by":"publisher","unstructured":"Thangamani S, Mohammad H, Abushahba MFN, Sobreira TJP, Seleem MN. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. Int J Antimicrob Agents [Internet]. 2016;47(3):195\u2013201. Available from: https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.016","DOI":"10.1016\/j.ijantimicag.2015.12.016"},{"key":"11359_CR17","doi-asserted-by":"crossref","unstructured":"Od\u00edlia Antunes Fernandes S. Repurposing the thalidomide to the treatment of irinotecan-induced intestinal mucositis: An old drug to a new use. Glob J Pharm Pharm Sci [Internet]. 2018;6(2). Available from: https:\/\/juniperpublishers.com\/gjpps\/GJPPS.MS.ID.555682.php","DOI":"10.19080\/GJPPS.2018.06.555682"},{"key":"11359_CR18","doi-asserted-by":"publisher","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov [Internet]. 2019;18(1):41\u201358. Available from: https:\/\/doi.org\/10.1038\/nrd.2018.168","DOI":"10.1038\/nrd.2018.168"},{"key":"11359_CR19","doi-asserted-by":"publisher","unstructured":"Lima WG, Alves-Nascimento LA, Andrade JT, Vieira L, de Azambuja Ribeiro RIM, Thom\u00e9 RG et al. Are the Statins promising antifungal agents against invasive candidiasis? Biomed Pharmacother [Internet]. 2019;111:270\u201381. Available from: https:\/\/doi.org\/10.1016\/j.biopha.2018.12.076","DOI":"10.1016\/j.biopha.2018.12.076"},{"key":"11359_CR20","doi-asserted-by":"publisher","unstructured":"Santos FRS, Nunes DAF, Lima WG, Davyt D, Santos LL, Taranto AG et al. Identification of Zika Virus NS2B-NS3 Protease Inhibitors by Structure-Based Virtual Screening and Drug Repurposing Approaches. J Chem Inf Model [Internet]. 2020;60(2):731\u20137. Available from: https:\/\/doi.org\/10.1021\/acs.jcim.9b00933","DOI":"10.1021\/acs.jcim.9b00933"},{"key":"11359_CR21","doi-asserted-by":"publisher","unstructured":"Kumar S, Basu M, Ghosh P, Pal U, Ghosh MK. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes Dis [Internet]. 2023;10(4):1402\u201328. Available from: https:\/\/doi.org\/10.1016\/j.gendis.2022.12.019","DOI":"10.1016\/j.gendis.2022.12.019"},{"key":"11359_CR22","doi-asserted-by":"publisher","unstructured":"Zapata-Cardona MI, Florez-Alvarez L, Guerra-Sandoval AL, Chvatal-Medina M, Guerra-Almonacid CM, Hincapie-Garcia J et al. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach. AIMS Microbiol [Internet]. 2023;9(1):20\u201340. Available from: https:\/\/doi.org\/10.3934\/microbiol.2023002","DOI":"10.3934\/microbiol.2023002"},{"key":"11359_CR23","doi-asserted-by":"publisher","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov [Internet]. 2020;6:14. Available from: https:\/\/doi.org\/10.1038\/s41421-020-0153-3","DOI":"10.1038\/s41421-020-0153-3"},{"key":"11359_CR24","doi-asserted-by":"publisher","unstructured":"Axfors C, Schmitt AM, Janiaud P, Van\u2019t Hooft J, Abd-Elsalam S, Abdo EF et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun [Internet]. 2021;12(1):2349. Available from: https:\/\/doi.org\/10.1038\/s41467-021-22446-z","DOI":"10.1038\/s41467-021-22446-z"},{"key":"11359_CR25","doi-asserted-by":"publisher","unstructured":"Bignardi PR, Vengrus CS, Aquino BM, Cerci Neto A. Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathog Glob Health [Internet]. 2021;115(3):139\u201350. Available from: https:\/\/doi.org\/10.1080\/20477724.2021.1884807","DOI":"10.1080\/20477724.2021.1884807"},{"key":"11359_CR26","doi-asserted-by":"publisher","unstructured":"Abuelazm M, Ghanem A, Awad AK, Farahat RA, Labieb F, Katamesh BE et al. The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig [Internet]. 2022;42(12):1031\u201347. Available from: https:\/\/doi.org\/10.1007\/s40261-022-01213-y","DOI":"10.1007\/s40261-022-01213-y"},{"key":"11359_CR27","doi-asserted-by":"publisher","unstructured":"Marcolino MS, Meira KC, Guimar\u00e3es NS, Motta PP, Chagas VS, Kelles SMB et al. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infect Dis [Internet]. 2022;22(1):639. Available from: https:\/\/doi.org\/10.1186\/s12879-022-07589-8","DOI":"10.1186\/s12879-022-07589-8"},{"key":"11359_CR28","doi-asserted-by":"crossref","unstructured":"Chen YW, Yiu CPB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3\u00a0C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res [Internet]. 2020;9:129. Available from: https:\/\/f1000research.com\/articles\/9-129\/v1","DOI":"10.12688\/f1000research.22457.2"},{"key":"11359_CR29","doi-asserted-by":"publisher","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA [Internet]. 2020;323(18):1824\u201336. Available from: https:\/\/doi.org\/10.1001\/jama.2020.6019","DOI":"10.1001\/jama.2020.6019"},{"key":"11359_CR30","doi-asserted-by":"publisher","unstructured":"Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019- nCoV). Nat Rev Drug Discov [Internet]. 2020;19(3):149\u201350. Available from: https:\/\/doi.org\/10.1038\/d41573-020-00016-0","DOI":"10.1038\/d41573-020-00016-0"},{"key":"11359_CR31","doi-asserted-by":"publisher","unstructured":"Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res [Internet]. 2020;19(11):4690\u20137. Available from: https:\/\/doi.org\/10.1021\/acs.jproteome.0c00392","DOI":"10.1021\/acs.jproteome.0c00392"},{"key":"11359_CR32","doi-asserted-by":"publisher","unstructured":"Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an perspective. J Biomol Struct Dyn [Internet]. 2021;39(9):3204\u201312. Available from: https:\/\/doi.org\/10.1080\/07391102.2020.1761882","DOI":"10.1080\/07391102.2020.1761882"},{"key":"11359_CR33","doi-asserted-by":"publisher","unstructured":"Elfiky AA, Ribavirin. Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci [Internet]. 2020;253:117592. Available from: https:\/\/doi.org\/10.1016\/j.lfs.2020.117592","DOI":"10.1016\/j.lfs.2020.117592"},{"key":"11359_CR34","doi-asserted-by":"publisher","unstructured":"Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S et al. Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase [Internet]. bioRxiv. 2020 [cited 2024 Aug 14]. p. 2020.04.03.022939. Available from: https:\/\/www.biorxiv.org\/content\/https:\/\/doi.org\/10.1101\/2020.04.03.022939v1.abstract","DOI":"10.1101\/2020.04.03.022939v1.abstract"},{"key":"11359_CR35","doi-asserted-by":"publisher","unstructured":"Parienti JJ, Prazuck T, Peyro-Saint-Paul L, Fournier A, Valentin C, Brucato S et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine [Internet]. 2021;38:100993. Available from: https:\/\/doi.org\/10.1016\/j.eclinm.2021.100993","DOI":"10.1016\/j.eclinm.2021.100993"},{"key":"11359_CR36","doi-asserted-by":"publisher","unstructured":"Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C et al. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect [Internet]. 2020;8(6):e00674. Available from: https:\/\/doi.org\/10.1002\/prp2.674","DOI":"10.1002\/prp2.674"},{"key":"11359_CR37","doi-asserted-by":"publisher","unstructured":"Del Amo J, Polo R, Moreno S, D\u00edaz A, Mart\u00ednez E, Arribas JR et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study. Ann Intern Med [Internet]. 2020;173(7):536\u201341. Available from: https:\/\/doi.org\/10.7326\/M20-3689","DOI":"10.7326\/M20-3689"},{"key":"11359_CR38","doi-asserted-by":"publisher","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis [Internet]. 2021;73(7):e2005\u201315. Available from: https:\/\/doi.org\/10.1093\/cid\/ciaa1198","DOI":"10.1093\/cid\/ciaa1198"},{"key":"11359_CR39","doi-asserted-by":"publisher","unstructured":"Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L et al. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS [Internet]. 2022;36(12):1689\u201396. Available from: https:\/\/doi.org\/10.1097\/QAD.0000000000003314","DOI":"10.1097\/QAD.0000000000003314"},{"key":"11359_CR40","doi-asserted-by":"publisher","unstructured":"Nomah DK, Reyes-Urue\u00f1a J, D\u00edaz Y, Moreno S, Aceiton J, Bruguera A et al. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. J Antimicrob Chemother [Internet]. 2022;77(8):2265\u201373. Available from: https:\/\/doi.org\/10.1093\/jac\/dkac177","DOI":"10.1093\/jac\/dkac177"},{"key":"11359_CR41","unstructured":"Higgins J, Welch V. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2024 Aug 14]. Available from: www.training.cochrane.org\/handbook"},{"key":"11359_CR42","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;372:n71. Available from: https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"11359_CR43","doi-asserted-by":"publisher","unstructured":"Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc [Internet]. 2018;106(4):420\u201331. Available from: https:\/\/doi.org\/10.5195\/jmla.2018.345","DOI":"10.5195\/jmla.2018.345"},{"key":"11359_CR44","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev [Internet]. 2016;5(1):210. Available from: https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"11359_CR45","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019;366:l4898. Available from: https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"11359_CR46","doi-asserted-by":"publisher","unstructured":"Polo R, Garc\u00eda-Alb\u00e9niz X, Ter\u00e1n C, Morales M, Rial-Crestelo D, Garcinu\u00f1o MA et al. Daily tenofovir disoproxil fumarate\/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers. Clin Microbiol Infect [Internet]. 2023;29(1):85\u201393. Available from: https:\/\/doi.org\/10.1016\/j.cmi.2022.07.006","DOI":"10.1016\/j.cmi.2022.07.006"},{"key":"11359_CR47","doi-asserted-by":"publisher","unstructured":"Arruda EAG, Pires-Neto RJ, Medeiros MS, Quirino-Filho J, Clementino M, Gondim RNDG et al. Clinical trial of efficacy and toxicity of disoproxil tenofovir fumarate and emtricitabine for mild to moderate SARS-CoV-2 infections [Internet]. bioRxiv. 2021. Available from: http:\/\/medrxiv.org\/lookup\/doi\/https:\/\/doi.org\/10.1101\/2021.09.28.21264242","DOI":"10.1101\/2021.09.28.21264242"},{"key":"11359_CR48","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 May 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04519125"},{"key":"11359_CR49","unstructured":"ClinicalTrials.gov [Internet]. [cited 2025 May 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04405271"},{"key":"11359_CR50","doi-asserted-by":"crossref","unstructured":"Clososki G, Soldi R, da Silva R, Guaratini T, Lopes J, Pereira P et al. Tenofovir disoproxil fumarate: New chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc [Internet]. 2020; Available from: https:\/\/jbcs.sbq.org.br\/audiencia_pdf.asp?aid2=10947%26nomeArquivo=2020-0254CO.pdf","DOI":"10.21577\/0103-5053.20200106"},{"key":"11359_CR51","doi-asserted-by":"publisher","unstructured":"Gait\u00e1n-Duarte HG, \u00c1lvarez-Moreno C, Rinc\u00f3n-Rodr\u00edguez CJ, Yomayusa-Gonz\u00e1lez N, Cort\u00e9s JA, Villar JC et al. Effectiveness of rosuvastatin plus colchicine, emtricitabine\/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine [Internet]. 2022;43:101242. Available from: https:\/\/doi.org\/10.1016\/j.eclinm.2021.101242","DOI":"10.1016\/j.eclinm.2021.101242"},{"key":"11359_CR52","doi-asserted-by":"publisher","unstructured":"Montejano R, de la Calle-Prieto F, Velasco M, Guijarro C, Queiruga-Parada J, Jim\u00e9nez-Gonz\u00e1lez M et al. Tenofovir Disoproxil Fumarate\/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. Clin Infect Dis [Internet]. 2023;76(3):e116\u201325. Available from: https:\/\/doi.org\/10.1093\/cid\/ciac628","DOI":"10.1093\/cid\/ciac628"},{"key":"11359_CR53","doi-asserted-by":"publisher","unstructured":"Yazdan Pouri N, Shokati Eshkiki Z, Talebi A, Cheraghian B, Ahmadi F, Neisi N et al. Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial. BMC Pharmacol Toxicol [Internet]. 2024;25(1):78. Available from: https:\/\/doi.org\/10.1186\/s40360-024-00781-3","DOI":"10.1186\/s40360-024-00781-3"},{"key":"11359_CR54","doi-asserted-by":"publisher","unstructured":"Getz K, Smith Z, Shafner L, Hanina A. Assessing the scope and predictors of intentional dose non-adherence in clinical trials. Ther Innov Regul Sci [Internet]. 2020;54(6):1330\u20138. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s43441-020-00155-x","DOI":"10.1007\/s43441-020-00155-x"},{"key":"11359_CR55","doi-asserted-by":"publisher","unstructured":"Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval approach. J Clin Epidemiol [Internet]. 2013;66(2):197\u2013201. Available from: https:\/\/doi.org\/10.1016\/j.jclinepi.2012.09.002","DOI":"10.1016\/j.jclinepi.2012.09.002"},{"key":"11359_CR56","doi-asserted-by":"crossref","unstructured":"Julious SA. Sample Sizes for Clinical Trials [Internet]., Chapman. and Hall\/CRC; 2009. Available from: https:\/\/books.google.com\/books\/about\/Sample_Sizes_for_Clinical_Trials.html?hl=%26id=Jz3GmAEACAAJ","DOI":"10.1201\/9781584887409"},{"key":"11359_CR57","doi-asserted-by":"publisher","unstructured":"Cheema HA, Jafar U, Shahid A, Masood W, Usman M, Hermis AH et al. Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials. BMJ Open [Internet]. 2024;14(4):e074373. Available from: https:\/\/doi.org\/10.1136\/bmjopen-2023-074373","DOI":"10.1136\/bmjopen-2023-074373"},{"key":"11359_CR58","doi-asserted-by":"publisher","unstructured":"Movahed F, Heidari E, Dehbozorgi M, Goodarzi S, Abianeh FE, Abbasi M et al. Statins for the treatment of COVID-19 patients: an updated meta-analysis of randomized controlled trials. Discov Med [Internet]. 2024;1(1). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s44337-024-00092-w","DOI":"10.1007\/s44337-024-00092-w"},{"key":"11359_CR59","doi-asserted-by":"publisher","unstructured":"McDonnell JM, Dalton DM, Ahern DP, Welch-Phillips A, Butler JS. Methods to Mitigate Industry Influence in Industry Sponsored Research. Clin Spine Surg [Internet]. 2021;34(4):143\u20135. Available from: https:\/\/doi.org\/10.1097\/BSD.0000000000001098","DOI":"10.1097\/BSD.0000000000001098"},{"key":"11359_CR60","doi-asserted-by":"publisher","unstructured":"Pocock SJ, Stone GW. The Primary Outcome Fails - What Next? N Engl J Med [Internet]. 2016;375(9):861\u201370. Available from: https:\/\/doi.org\/10.1056\/NEJMra1510064","DOI":"10.1056\/NEJMra1510064"},{"key":"11359_CR61","doi-asserted-by":"publisher","unstructured":"Dettori JR, Norvell DC, Chapman JR. Is the Sample Size Big Enough? 4 Things You Need to Know! Global Spine J [Internet]. 2022;12(5):1027\u20138. Available from: https:\/\/doi.org\/10.1177\/21925682211055711","DOI":"10.1177\/21925682211055711"},{"key":"11359_CR62","doi-asserted-by":"publisher","unstructured":"Smith CJ. How many patients do I need? Sample size and power calculations. Phlebology [Internet]. 2011 [cited 2025 May 19]; Available from: https:\/\/journals.sagepub.com\/doi\/https:\/\/doi.org\/10.1258\/phleb.2010.010j01","DOI":"10.1258\/phleb.2010.010j01"},{"key":"11359_CR63","doi-asserted-by":"publisher","unstructured":"Nguyen NT, Chinn J, Kirby K, Hohmann SF, Amin A. Outcomes of COVID-19 adults managed in an outpatient versus hospital setting. PLoS One [Internet]. 2022;17(2):e0263813. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0263813","DOI":"10.1371\/journal.pone.0263813"},{"key":"11359_CR64","doi-asserted-by":"publisher","unstructured":"Cilloniz C, Motos A, Peric\u00e0s JM, Casta\u00f1eda TG, Gabarr\u00fas A, Ferrer R et al. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain. Pulmonology [Internet]. 2023;29(5):362\u201374. Available from: https:\/\/doi.org\/10.1016\/j.pulmoe.2023.01.007","DOI":"10.1016\/j.pulmoe.2023.01.007"},{"key":"11359_CR65","doi-asserted-by":"publisher","unstructured":"Endeshaw Y, Campbell K. Advanced age, comorbidity and the risk of mortality in COVID-19 infection. J Natl Med Assoc [Internet]. 2022;114(5):512\u20137. Available from: https:\/\/doi.org\/10.1016\/j.jnma.2022.06.005","DOI":"10.1016\/j.jnma.2022.06.005"},{"key":"11359_CR66","doi-asserted-by":"publisher","unstructured":"Costenaro P, Minotti C, Barbieri E, Giaquinto C, Don\u00e0 D. SARS-CoV-2 infection in people living with HIV: a systematic review. Rev Med Virol [Internet]. 2021;31(1):1\u201312. Available from: https:\/\/doi.org\/10.1002\/rmv.2155","DOI":"10.1002\/rmv.2155"},{"key":"11359_CR67","doi-asserted-by":"publisher","unstructured":"Mellor MM, Bast AC, Jones NR, Roberts NW, Ord\u00f3\u00f1ez-Mena JM, Reith AJM et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS [Internet]. 2021;35(4):F1\u201310. Available from: https:\/\/doi.org\/10.1097\/QAD.0000000000002836","DOI":"10.1097\/QAD.0000000000002836"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11359-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:01:23Z","timestamp":1753948883000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11359-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11359"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11359-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"965"}}